2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2673

Glandular Ultrasonography in Primary SjöGren Syndrome: Clinical and Laboratory Correlation
Abstract Number: 2078

Global Ethnic and Geographic Differences in the Clinical Features of ANCA-Associated Vasculitis
Abstract Number: 438

Glucocorticoid Adverse Effects – the Patient Perspective
Abstract Number: 1031

Glucocorticoid Receptor Dimerization in Stromal Cells Modulates Macrophage Polarization during Serum Transfer-Induced Arthritis
Abstract Number: 2544

Glucocorticoid Treatment for 12 Weeks in Early Rheumatoid Arthritis Is Related to an Increase in BMI
Abstract Number: 2541

Glucocorticoid Use and Low Thoracic Bone Mineral Density Are Predictors for Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of the Tomorrow Study
Abstract Number: 2246

Glucocorticoids in Early Rheumatoid Arthritis Management, Friend or Foe?
Abstract Number: 288

Glucose Homeostasis Influences the Risk of Incident Knee Osteoarthritis
Abstract Number: 1451

Glutamine Metabolism Plays a Crucial Role in the Pathogenesis of Rheumatoid Arthritis
Abstract Number: 584

Glycoprotein VI: A Potential Target for ACPA-Mediated Platelet Activation?
Abstract Number: 629

Golimumab Improves Patient-Reported Outcomes and Socio- and Health-Economic Parameters in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS): Results from a Non-Interventional Clinical Evaluation in Germany
Abstract Number: 413

Golimumab in Refractory Uveitis Associated to Juvenile Idiopathic Arthritis. Multicenter Study of 7 Cases and Literature Review
Abstract Number: 2301

Gout and Subsequent Risk of Incident Erectile Dysfunction: A Population-Based Cohort Study from the United Kingdom
Abstract Number: 519

Greater Fatigue at Baseline and Female Gender Predict Worse Disability in Early RA Despite Treatment to Target: A Comparison of Two Observational Cohort Studies from the United Kingdom
Abstract Number: 2998

Gut Microbiota Induce IGF-1 and Promote Bone Formation and Growth

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].